Drugmakers to pay $82M in pricing case; Novo says Victoza didn't cause patients' deaths;

 @FiercePharma: Novartis to pay Gilenya patients' bills. Article | Follow @FiercePharma

> About three dozen drugmakers have agreed to pay $82 million to settle claims that they overcharged Hawaii's Medicaid program by publishing average wholesale prices that actually exceeded prices paid by pharmacies. Report

> Danish drugmaker Novo Nordisk says two patients treated with its Victoza Type 2 diabetes drug died in Japan, but the fatalities were caused by inappropriate discontinuation of insulin. Report

> Plans by Leo Pharma to move up to a quarter of its operations abroad over the next four years will result in the loss of 150 Danish jobs. Report

> Takeda's bone cancer drug Mepact has been rejected by Britain's health costs watchdog because of concerns about its efficacy and high cost to the taxpayer-funded National Health Service. Report

> Roche will announce by the end of the year details of how it will cut costs, CEO Severin Schwan (photo) told reporters in Tokyo. Report

> Watson Pharmaceuticals settled a patent infringement lawsuit brought by Endo Pharmaceuticals and will start selling a generic version of Endo's pain drug Opana ER in September 2012. Report

Biotech News

 @FierceBiotech: Novartis, Venter team on faster vax development. Article | Follow @FierceBiotech

 @JohnCFierce: I'll be moderating a breakfast session Oct. 27 in Boston with some top trial experts. Markers, I-Spy 2 and more. Story |  Follow @JohnCFierce

> Sanofi-Genzyme takeover bid gets heated. Report

> Boehringer stops female libido drug program. Story

> Onyx delays cancer app on manufacturing issues. Report

> Cytomedix gets $13M in RDO. Item

> Inviragen, PharmaJet land $15.5M for needle-free dengue vax. Article

And Finally... The shift toward more copycat drug sales may even be hard on generics makers because they've traditionally been as dependent on Big Pharma's innovation as those drugmakers are. Report